BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Elbit Medical Imaging Ltd. (EMITF) Selected for Listing on Nasdaq Global Select Market Company Meets Highest Listing Standards of any Exchange in the World


12/19/2007 8:38:42 AM

TEL-AVIV, Israel, Dec. 19 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. ("EI" or the "Company") today announced that it has qualified to be listed on the NASDAQ Global Select Market effective January 1, 2008, and will continue to trade under the symbol EMITF. This upgraded listing is a result of meeting NASDAQ's highest initial listing standards based on financial and liquidity requirements. Prior to the change, the Company had been listed on the NASDAQ Global Market.

Mr. Shimon Yitzhaki, Elbit Imaging's President, commented: "We are pleased to have achieved this premier designation by meeting NASDAQ's stringent listing requirements, enabling our shares to be traded alongside NASDAQ's top- tier companies. This improved trading status reflects the Company's continued growth and enhanced market share, and is expected to give our stock greater visibility."

About Elbit Imaging Ltd.

Elbit Imaging Ltd. ("EI") is a subsidiary of Europe Israel (M.M.S.) Ltd. EI's activities are divided into the following principal fields: (i) Initiation, construction, operation, management and sale of shopping and entertainment centers in Israel, Central and Eastern Europe and India; (ii) Hotels ownership, primarily in major European cities, as well as operation, management and sale of same through its subsidiary, Elscint Ltd.; (iii) Investments in the research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, through its subsidiary, InSightec Ltd.; and (iv) Other activities consisting of the distribution and marketing of women's fashion and accessories through our wholly-owned Israeli subsidiary, Elbit Trade & Retail Ltd., and venture- capital investments.

About NASDAQ

NASDAQ is the largest U.S. electronic stock market. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit www.nasdaq.com or the NASDAQ Newsroom at www.nasdaq.com/newsroom/.

Any forward looking statements with respect to EI's business, financial condition and results of operations included in this release are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward looking statements, including, but not limited to, ability to find suitable locations, receipt of approvals and permits for zoning and construction, delays in construction, dependency on partners in the hotels business, competition, risks relating to operations in Eastern Europe and Asia (including India) and risks relating to our image guided treatment, economic conditions, as well as certain other risk factors which are detailed from time to time in EI's filings with the Securities and Exchange Commission including, without limitation, Annual Report on Form 20-F for the fiscal year ended December 31, 2006, filed with the Securities and Exchange Commission on July 3, 2007.

syitzhaki@elbitimaging.com lwolf-creutzfeldt@hfgcg.comdudim@elbitimaging.com

CONTACT: Company Contact: Shimon Yitzhaki, President, Elbit Imaging Ltd.,
+972-3-608-6000, syitzhaki@elbitimaging.com, or Dudi Machluf, CFO, Elbit
Imaging Ltd., +972-3-608-6024, dudim@elbitimaging.com; or Investors: Leslie
Wolf-Creutzfeldt of The Global Consulting Group for Elbit Imaging Ltd.,
+1-646-284-9472, lwolf-creutzfeldt@hfgcg.com

Web site: http://www.nasdaq.com/
http://www.nasdaq.com/newsroom//



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES